Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy

Table 1 Patient characteristics n (%)

Characteristics	Patients
Sexe
Male	34 (67.3)
Female	18 (32.7)
Age
< 80	9 (17.0)
≥ 80	43 (83.0)
Tumor location
Colorectal	34 (65.4)
Pancreas	18 (34.6)
Metastasis
≤ 1	26 (50.0)
> 1	26 (50.0)
ECOG performance status
[0-1]	43 (82.7)
[2-3]	9 (17.3)
Comorbidities
No	15 (28.8)
Yes	37 (71.2)
Cardiac comorbidities
No	40 (76.9)
Yes	12 (23.1)
Pulmonary comorbidities
No	47 (90.4)
Yes	5 (9.6)
Hepatic comorbidities
No	52 (100.0)
Yes	0 (0.0)
Albumin level
< 30 g/L	16 (30.8)
≥ 30 g/L	21 (40.4)
Number of usual drugs
< 3	22 (42.3)
≥ 4	30 (57.7)
Charlson comorbidities index
< 10	32 (61.5)
≥ 10	20 (38.5)
Initial autonomy
No	3 (5.8)
Yes	49 (94.2)

Table 2 Observed toxicity according Common Terminology Criteria for Adverse Events v 4.03 (n = 52) n (%)

	CTCAE v 4.03
	All grades	Severe1
Hematological
Anemia	28 (53.8)	5 (9.6)
Neutropenia	24 (46.2)	17 (32.7)
Thrombocytopenia	14 (26.9)	3 (5.8)
Non Hematological
Diarrhea	35 (67.3)	13 (25.0)
Nausea and vomiting	22 (42.3)	5 (9.6)
Asthenia	49 (94.2)	5 (9.6)
Peripheral Neutropenia	17 (32.7)	4 (7.7)
Hepatic toxicity	4 (7.7)	1 (1.9)

¹Grade 3-4 according to the CTCAE version 4.03. CTCAE: Common Terminology Criteria for Adverse Events.

Table 3 Univariate and multivariate analysis by subgroup for time under treatment

	Univariate analysis				Multivariate analysis
	HR	95%CI		P vaule	HR	95%CI		P vaule
Tumor location				0.1204				0.4288
CR	Ref				Ref
Pancréas	1.615	0.882	2.958		1.316	0.667	2.599
Metastatic sites				0.0478				0.1405
0-1	Ref				Ref
≥ 2	0.56	0.315	0.994		0.613	0.32	1.175
Age				0.2105				0.1637
< 75	Ref				Ref
≥ 75	0.692	0.389	1.231		0.664	0.373	1.182
Age				0.371
< 80	Ref
≥ 80	1.394	0.673	2.889
Comorbidities				0.979
No	Ref
Yes	1.008	0.549	1.851
Neoadjuvant chemotherapy				0.2339
No	Ref
Yes	2.432	0.563	10.5
Initial autonomy (J0)				0.9059
No	Ref
Yes	0.932	0.288	3.018
Charlson comorbidities index				0.7659
< 10	Ref
≥ 10	0.915	0.511	1.639
ECOG performance status				0.5046
0-1	Ref
≥ 2	1.281	0.618	2.655
Sexe				0.7228
Male	Ref
Female	0.856	0.361	2.026
Number of usual drugs				0.3057
< 4	Ref
≥ 4	1.34	0.765	2.347

Table 4 Univariate and multivariate analysis by subgroup for overall survival

	Univariate analysis				Multivariate analysis
	HR	95%CI		P vaule	HR	95%CI		P vaule
Tumor location				< 10-4				< 10-4
CR	Ref				Ref
Pancréas	6.362	2.963	13.66		5.816	2.47	13.693
Metastatic sites				0.0634				0.9874
0-1	Ref				Ref
≥ 2	0.555	0.298	1.034		1.006	0.498	2.032
Age				0.5721				0.7614
< 75	Ref				Ref
≥ 75	1.184	0.659	2.124		1.096	0.607	1.976
Age				0.5365				0.274
< 80	Ref				Ref
≥ 80	1.277	0.588	2.774		1.611	0.686	3.786
Sexe				0.1178				0.4136
Male	Ref				Ref
Female	0.464	0.177	1.215		0.634	0.212	1.891
Comorbidities				0.0899				0.8701
No	Ref				Ref
Yes	1.787	0.914	3.495		1.066	0.494	2.301
Initial autonomy				0.7372
No	Ref
Yes	1.277	0.306	5.336
Charlson comorbidities index				0.7507
< 10	Ref
≥ 10	1.101	0.608	1.992
ECOG performance status				0.6426
0-1	Ref
≥ 2	0.833	0.385	1.802
Number of usual drugs				0.6116
< 4	Ref
≥ 4	1.169	0.64	2.132